BSE: 524652
To view real time prices Login to your account
Already an existing customer? - Login Now!
BSE Click here to view BSE data
Live Chart
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
Div yield:

Fundamental analysis


0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Underperformed both Sector by -22.44% and Sensex by -37.76%
MARKET CAP (Micro Cap Stock)Rs 54 Cr
PE (TTM) -1.39
PE Ratio-1.35
Price to Book Value-0.07
EV to EBIT140.39
EV to EBITDA28.15
EV to Capital Employed3.58
EV to Sales2.62
PEG Ratio0.00
Dividend YieldNA
ROCE (Latest)4.44%
ROE (Latest)Negative BV
NameDec 22Sep 22
Promoters (Change:0.00) 55.58%55.58%
FIIs (Change:-0.00) 0%0%
Mutual Funds (Change:-0.00) 0%0%
Insurance Companies (Change:0.00) 0%0%
Other DIIs (Change:0.01) 0.01%0%
Non Institution (Change:0.00) 44.42%44.42%

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000


Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %


Frequently Asked Questions

What is the Share price of IND-SWIFT LTD. (INDSWFTLTD)?

IND-SWIFT LTD. (INDSWFTLTD) share price as of February 4, 2023, on NSE is Rs 9.40 (NSE) and Rs 9.55 (BSE) on BSE.


Yes, You can buy IND-SWIFT LTD. (INDSWFTLTD) shares by opening a Demat account with Angel One.

How do I buy IND-SWIFT LTD. (INDSWFTLTD) from Angel One?

IND-SWIFT LTD. (INDSWFTLTD) share can be brought through the following modes:
  1. Direct investment: You can buy IND-SWIFT LTD. (INDSWFTLTD) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to IND-SWIFT LTD. (INDSWFTLTD) shares.

In which sector do IND-SWIFT LTD. (INDSWFTLTD) belong?

IND-SWIFT LTD. (INDSWFTLTD) belongs to Pharma.


Today's live share price for IND-SWIFT LTD. is NSE: ₹ 9.40, BSE: ₹ 9.55 with a current market capitalization of .

Ind-Swift Ltd is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of pharmaceutical finished dosage. The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables. The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty. Ind-Swift Ltd was incorporated in the year 1986. In the year 1991, the company set up a manufacturing facility for injectables and eye/ear drops. In the year 1995, they incorporated Ind-Swift Laboratories Ltd for initiating a backward integration into the manufacturing of APIs and advanced intermediates. In the year 1997, the company commissioned a multipurpose plant with five independent blocks erected as per US FDA standards, designed by Quara, Switzerland. In addition, they launched a Marketing Division with the name Ind-Swift Health Care. In the year 2000, the company launched Super Specialty Division, which is focusing on Cardiology and Diabetology segments. In the year 2001, they launched Pioglitazone and Candesartan, in which the company is the second to launch this product in India. In addition, they launched Institution/Hospital Division. In the year 2003, the company launched another division by the name Ind-Swift Biosciences. They entered into formulations export to six countries and filed patent in US for Clarithromycin. In the year 2004, the company launched Mukur Division with focus on ophthalmology, neuropsychiatry and ENT. They launched Launched Nitazoxanide, an antidiarrhoeal drug, first time in India after successful clinical trials. In addition, they launched another division by the name Resurgence catering to the Anesthesiology and Oncology segments. The company opened first overseas office in New Jersey, USA During the year 2004-05, the company launched combination of Nitazoxanide and Ofloxacin, with the brand name Netazox-OF, first time in Asia. They commenced commercial production in their new formulation facility at Jammu, J&K. During the year 2005-06, the company introduced various new product ranges in the domestic market through their nine marketing divisions. The new product launches included the launch of a unique combination of the Quinoline derivative, anti-diarrheal and anti-bacterial drug that was launched for the first time in India after completion of the successful clinical trials. They also launched the new marketing division namely Institutions & Hospitals division to look after the institutional sales. During the year, the company commissioned three new state of the art finished dosages facility at; Samba in Jammu & Kashmir; 100% EOU at Jawaharpur and an internationally benchmarked plant at Baddi in Himachal Pradesh. During the year 2006-07, the company developed and launched 65 new products and line extension. They launched their product in Kenya and Senegal. They also launched three new marketing division to focus on marketing of products for personal healthcare, veterinary and manufacturing and marketing of products for international companies. During the year, the company entered into licensing agreements with number of international Pharma companies for out licensing the technology of their patented products, Clarithromycin. They received approval of the Drug Authorities of Uganda and Tanzania, which will pave the way for the supply of their drugs in these countries. During the year 2007-08, the company's manufacturing unit at Parwanoo was upgraded as per WHO standards. The company's Global Business unit at Derabassi got MHRA & TGA approval. The manufacturing unit at Baddi received WHO GMP certification for tablet/SVP/Liquid manufacturing. In August 2007, the company commissioned a manufacturing facility at the same tax exempted zone and green plains of Baddi. This facility is for soft Gelatin Encapsultation with an annual capacity of 36 crore. In December 2007, they launched their new division 'Diagnozis' dealing in medical equipments & devices. The company also launched animal health care, which is absolutely a new concept with outsourced marketing.

Read more

Enjoy Zero Brokerage on Equity Delivery

Join our 1 Cr+ happy customers